About Edence Life Sciences Private Limited
Data last updated:
Edence Life Sciences Private Limited is a private limited company based in Mumbai, Maharashtra, India, a subsidiary of Sjm Capsol Private Limited and recognised as a startup by DPIIT. It operates in the preventive health supplements segment of the healthcare sector. It was incorporated on 29 September 2020 and has been in existence for over 6 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U74999MH2020PTC346908. Its GSTIN is 27AADCO2744B1ZS (Maharashtra).
The company has an authorised share capital of ₹5 Cr and a paid-up capital of ₹2 Cr. It was formerly known as Omniceutical Healthcare Private Limited. It is led by directors Sanjay Jaysinh Mariwala and Nihal Sanjay Mariwala.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Mumbai, Maharashtra.
As per the financials filed for FY 2025, the company reported a revenue of ₹5.74 Cr, a growth of 8% compared to the previous year. For the same year it recorded a net loss of ₹7.85 Cr (net margin -136.7%) and EBITDA of -₹6.42 Cr (EBITDA margin -111.8%). Revenue has grown at a compounded annual rate (CAGR) of 18% over three years.
The company has about 67 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Edence. The company has 2 deals on record (1 convertible or debt financing, 1 rights issue), with disclosed funding of ₹21.08 Cr; the latest was in February 2021. Its 10 peer companies in the Pharma industry (Formulations) are compared by revenue, 5 larger and 5 smaller; the largest is Harihar Pharmaceuticals Private Limited with revenue of ₹5.32 Cr. The company has 1 MSME Form 1 return on record for the period ending Mar 2022, listing 1 overdue payment to 1 micro and small supplier.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website edencels.com.
- EmailLocked
- TelephoneLocked
- Website
- Social MediaLocked
- Registered AddressL2 Unit No. 01 Lodha Excelus, N. M. Joshi Marg Mahalaxmi Agripada, Mumbai, Maharashtra, India – 400011
- IndustryHealthcare, Preventive Health Supplements
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Business Activity of Edence Life Sciences Private Limited
The main business activity of Edence Life Sciences is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Edence Life Sciences Private Limited FY 2025 filings available
Edence Life Sciences Private Limited reported revenue of ₹5.74 Cr (up 8% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR) of Edence Life Sciences Private Limited
Revenue has grown at a compounded annual rate (CAGR) of 18% over three years, including 8% growth in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Edence Life Sciences Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | ₹5.74 Cr | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | •••• | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | -₹6.42 Cr | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | -₹7.85 Cr | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Edence Life Sciences Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | -111.8% | •••• | •••• | •••• | •••• |
| Net Profit Margin | -136.7% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Edence Life Sciences are in the company report.
Financial statements from FY 2021
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Peer Comparison of Edence Life Sciences Private Limited
Edence Life Sciences Private Limited is compared with the companies closest to it by revenue in the Pharma industry (Formulations). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Edence Life Sciences Private Limited this company | ₹5.74 Cr (FY 2025) | •••• | •••• | 8.0% | •••• | Mumbai, Maharashtra, India |
| Harihar Pharmaceuticals Private Limited | ₹5.32 Cr (FY 2025) | •••• | •••• | 7.0% | •••• | Bolangir, Odisha, India |
| Lexus India Limited | ₹5.32 Cr (FY 2024) | •••• | •••• | 99.0% | •••• | New Delhi, Delhi, India |
| Meticulous Pharmaceticals Private Limited | ₹5.31 Cr (FY 2025) | •••• | •••• | 36.0% | •••• | Uttar Pradesh, India |
| Swastik Formulations Private Limited | ₹5.3 Cr (FY 2025) | •••• | •••• | 13.0% | •••• | Uttar Pradesh, India |
| Nupur Pharma Private Limited | ₹5.3 Cr (FY 2025) | •••• | •••• | -6.0% | •••• | Delhi, India |
| Synnova Intermediates Private Limited | ₹5.29 Cr (FY 2025) | •••• | •••• | 18325.0% | •••• | Mumbai, Maharashtra, India |
| Axolab Formulations Private Limited | ₹5.29 Cr (FY 2025) | •••• | •••• | 824.0% | •••• | Solan, Himachal Pradesh, India |
| SPR Oncocare Private Limited | ₹5.28 Cr (FY 2025) | •••• | •••• | 80.0% | •••• | Bangalore, Karnataka, India |
| Sure for Cure Farmulations (India ) Private Limited | ₹5.27 Cr (FY 2025) | •••• | •••• | -11.0% | •••• | Uttar Pradesh, India |
| Taj Pharma India Limited | ₹5.27 Cr (FY 2025) | •••• | •••• | 1274.0% | •••• | Mumbai, Maharashtra, India |
Peers are the five companies nearest above and the five nearest below Edence Life Sciences by revenue in the Pharma industry (Formulations), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Auditor Details of Edence Life Sciences Private Limited
Edence Life Sciences Private Limited is audited by CNK & associates LLP for the financial year 2022.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| CNK & associates LLP | Locked | Locked | Locked |
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Board of Directors of Edence Life Sciences Private Limited
Edence Life Sciences has 2 current directors and 1 former director. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Sanjay Jaysinh Mariwala | Director | 29 Sep 2020 | 6 Years 0 Months | Current |
| Nihal Sanjay Mariwala | Director | 29 Sep 2020 | 6 Years 0 Months | Current |
Ownership and Shareholding of Edence Life Sciences Private Limited
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Charges & Borrowings of Edence Life Sciences Private Limited
Edence Life Sciences Private Limited does not have any charges (loans) registered with the Registrar of Companies.
Deals & Funding of Edence Life Sciences Private Limited
Edence Life Sciences Private Limited has 2 deals on record (1 convertible or debt financing, 1 rights issue), with disclosed funding of ₹21.08 Cr; the latest was in February 2021.
Deals on record (1 of 2)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Feb 2021 | Rights issue | ₹1.99 Cr | Investors: SJM Capsol Private Limited |
Full deal history
All 2 deals with amounts, valuations, instruments and every party are in the company report.
- Every funding round and share transfer
- Amounts and valuations
- Investors, buyers and sellers
- Instruments and deal dates
Verified entity values are shown only after access is granted.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
MSME Payment Delays by Edence Life Sciences Private Limited
Edence Life Sciences Private Limited has 1 MSME Form 1 return on record for the period ending Mar 2022, listing 1 overdue payment to 1 micro and small supplier. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (1 of 1)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Walnut Advertising India Pvt.Ltd. | •••• | •••• | •••• |
Full MSME payment history
Every supplier, amount and due date from all 1 MSME Form 1 returns is in the company report.
- Every reported supplier due
- Amounts and due dates
- Reasons given in each return
- Period-by-period history
Verified entity values are shown only after access is granted.
Individuals and sole proprietors among the suppliers are not named. Amounts, due dates and filing dates are in the company report.
Associated Brands with Edence Life Sciences Private Limited
Edence Life Sciences operates one associated brand: Edence. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Nutraceutical supplements and evidence-driven health solutions in India. | edencels.com |
Employees and EPFO Compliance at Edence Life Sciences Private Limited
Edence Life Sciences Private Limited has a workforce of 67 employees as of Mar 31, 2024.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Recent Activity on Edence Life Sciences Private Limited
Edence Life Sciences Private Limited has 3 board changes on record since 2020: 2 appointments and 1 cessation. The latest: Ashoke Roy ceased to be Director on 22 Jul 2022.
Credit Ratings, Litigation & Regulatory Alerts for Edence Life Sciences Private Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Edence Life Sciences Private Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Edence Life Sciences Private Limited
Edence Life Sciences has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AADCO2744B1ZS | Maharashtra | Active | 12 Oct 2020 |
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Edence Life Sciences Private Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Edence Life Sciences Private Limited
Edence Life Sciences is an active private limited company based in Mumbai, Maharashtra, India. The company works in preventive health supplements, within the healthcare industry. It was incorporated on 29 September 2020 (6+ years old) and is registered under CIN U74999MH2020PTC346908.
Edence Life Sciences reported revenue of ₹5.74 Cr for FY 2025 (up 8% YoY).
Edence Life Sciences has 2 current directors:
- Sanjay Jaysinh Mariwala - Director
- Nihal Sanjay Mariwala - Director
Edence Life Sciences reported a net loss of ₹7.85 Cr (net margin -136.7%) and EBITDA of -₹6.42 Cr (EBITDA margin -111.8%) for FY 2025, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Edence Life Sciences is 18% over three years. In the latest year (FY 2025) revenue rose 8%. CAGR is the steady yearly rate that links the first and the last year.
The GSTIN of Edence Life Sciences is 27AADCO2744B1ZS, registered in Maharashtra.
The CIN (Corporate Identification Number) of Edence Life Sciences is U74999MH2020PTC346908. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Edence Life Sciences was incorporated on 29 September 2020, making it 6+ years old. It is registered with the Registrar of Companies, Mumbai.
Edence Life Sciences has 2 deals on record (1 convertible or debt financing, 1 rights issue), with disclosed funding of ₹21.08 Cr; the latest was in February 2021.
The peers of Edence Life Sciences by revenue are Harihar Pharmaceuticals Private Limited, Lexus India Limited, Meticulous Pharmaceticals Private Limited, Swastik Formulations Private Limited, Nupur Pharma Private Limited and 5 more, all in the Pharma industry (Formulations).
Ashoke Roy ceased to be Director on 22 Jul 2022. Nihal Sanjay Mariwala was appointed as Director on 29 Sep 2020. Sanjay Jaysinh Mariwala was appointed as Director on 29 Sep 2020.
Yes, Edence Life Sciences is recognised as a startup by the Department for Promotion of Industry and Internal Trade (DPIIT).